Secarna Pharma

News

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.

News

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.